Item 9A. Controls and Procedures
Item 9A. Controls and Procedures.
Limitations on effectiveness of controls and procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Evaluation of disclosure controls and procedures
Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of December 31, 2024, our disclosure controls and procedures were effective at the reasonable assurance level.
Management’s annual report on internal control over financial reporting
The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with accounting principles generally accepted in the United States of America.
Our management, with the participation of our principal executive officer and principal financial officer, conducted an assessment of the effectiveness of the Company’s internal control over financial reporting based on criteria established in “Internal Control—Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on this assessment, the management of the Company concluded that the Company’s internal control over financial reporting was effective as of December 31, 2024. The Company's internal control over financial reporting as of December 31, 2024 has been audited by Deloitte & Touche LLP as stated in their report which appears herein.
Changes in Internal Control over Financial Reporting
94
Table of Contents
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item 9B. Other Information.
Rule 10b5-1 Trading Plans
In accordance with the disclosure requirements set forth in Item 408(a) of Regulation S-K, the following table discloses any officer (as defined in Rule 16a-1(f) under the Exchange Act), director, or entity controlled by such officer or director who adopted or terminated a contract, instruction, or written plan for the sale of securities of the Company intended to satisfy the affirmative defense of Rule 10b5-1(c) during the quarterly period ended December 31, 2024 :
Name
Title
Action Taken
Date of Action
Duration of Trading Arrangement
Aggregate Number of Securities to be Sold
The Michael Kirban 2010 Trust
A trust for the children of Michael Kirban (Executive Chairman)
Adoption
December 13, 2024
March 14, 2025 to March 31, 2026
Up to 100,000 shares of Common Stock
Other than as disclosed above, no other officer, director or entity controlled by such officer or director adopted , modified or terminated a contract, instruction or written plan for the purchase or sale of securities of the Company intended to satisfy the affirmative defense of Rule 10b5-1(c) or a non-Rule 10b5-1 trading arrangement.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not applicable.
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
The information required by this item will be included in our definitive proxy statement for our 2025 Annual Meeting of Stockholders, and such required information is incorporated herein by reference.
Item 11. Executive Compensation.
The information required by this item will be included in our definitive proxy statement for our 2025 Annual Meeting of Stockholders, and such information is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The information required by this item will be included in our definitive proxy statement for our 2025 Annual Meeting of Stockholders, and such information is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
The information required by this item will be included in our definitive proxy statement for our 2025 Annual Meeting of Stockholders, and such information is incorporated herein by reference.
Item 14. Principal Accountant Fees and Services.
The information required by this item will be included in our definitive proxy statement for our 2025 Annual Meeting of Stockholders, and such information is incorporated herein by reference.
95
Table of Contents
PART IV
Item 15. Exhibits and Financial Statement Schedules
(a)(1) Financial Statements.
See the listing of the consolidated financial statements included in Item 8 of this Annual Report on Form 10-K.
(a)(2) Financial Statement Schedules.
Separate financial schedules have been omitted because such information is inapplicable or is included in the financial statements or notes described above.
96
Table of Contents
(a)(3) Exhibits.
The following is a list of exhibits filed as part of this Annual Report on Form 10-K.
Incorporated by Reference Filed/
Exhibit
Number
Exhibit Description Form File No. Exhibit Filing Date
Furnished Herewith
3.1 Second Amended and Restated Certificate of Incorporation of The Vita Coco Company, Inc.
8-K 001-40950
3.1 10/25/21
3.2 Amended and Restated Bylaws of The Vita Coco Company, Inc.
8-K 001-40950
3.2 10/25/21
4.1 Specimen Common Stock Certificate of The Vita Coco Company, Inc.
S-1 333-259825
4.1 9/27/21
4.2 Description of Capital Stock.
10-K
001-40950
4.2
3/14/23
4.3+
Registration Rights Agreement, by and among The Vita Coco Company, Inc. and certain security holders of The Vita Coco Company, Inc., dated as of October 20, 2021.
8-K 001-40950
10.1 10/25/21
4.4+
Investor Rights Agreement, among The Vita Coco Company, Inc., Verlinvest Beverages SA, Michael Kirban and Ira Liran, dated as of October 20, 2021.
8-K 001-40950
10.2 10/25/21
4.5
Form of Indenture
S-3
333-271583
4.4
5/2/23
10.1+
Amendment to Credit Agreement, by and between All Market Inc., the Guarantors, and Wells Fargo Bank, National Association, dated as of January 11, 2021.
S-1 333 - 259825
10.1 9/27/21
10.2+
Second Amendment to Credit Agreement, by and between All Market Inc., the Guarantors, and Wells Fargo Bank, National Association, dated as of May 21, 2021.
S-1 333 - 259825
10.2 9/27/21
10.3+ Third Amendment to Credit Agreement, by and between The Vita Coco Company, Inc., the Guarantors, and Wells Fargo Bank, National Association, dated as of November 2, 2021 .
10-K 001-10950 10.3 3/14/22
10.4+ Fourth Amendment to the Credit Agreement, by and between The Vita Coco Company, Inc., the Guarantors, and Wells Fargo Bank, National Association, dated as of December 5, 2022.
10-K
001-40950
10.4
3/14/23
10.5+
F ifth Amendment to the Credit Agreement, by and between The Vita Coco Company, Inc., the Guarantors, and Wells Fargo Bank, National Association, dated as of February 14, 2025.
*
10.6†
All Market Inc. 2014 Stock Option And Restricted Stock Plan.
S-1/A 333-259825 10.3 10/12/21
10.7†
The Vita Coco Company, Inc. 2021 Incentive Award Plan .
10-K 001-40950
10.5
3/14/22
10.8†
The Vita Coco Company, Inc. 2021 Employee Stock Purchase Plan .
S-1/A 333-259825 10.5 10/12/21
10.9†
Form of Stock Option Grant Notice
10-K 001-40950
10.7
3/14/22
10.10†
Form of Restricted Stock Grant Notice
10-K 001-40950
10.8
3/14/22
97
Table of Contents
10.11†
Amended and Restated Employment Agreement, by and between The Vita Coco Company, Inc. and Michael Kirban, dated October 20, 2021.
10-Q 001-40950 10.5 11/17/21
10.12†
First Amendment to Employment Agreement, by and between The Vita Coco Company, Inc. and Michael Kirban, effective as of May 2, 2022.
10-Q 001-40950 10.1 11/10/22
10.13†
S econd Amendment to Amended and Restated Employment Agreement, by and between The Vita Coco Company, Inc. and Michael Kirban, dated March 4, 2024.
10-Q
001-40950
10.1
05/02/2024
10.14†
Amended and Restated Employment Agreement, by and between The Vita Coco Company, Inc. and Martin Roper, dated October 20, 2021.
10-Q 001-40950 10.6 11/17/21
10.15†
The Vita Coco Company, Inc. Non-Employee Director Compensation Policy.
*
10.16†
Form of Indemnification Agreement.
S-1/A 333-259825 10.7 10/12/21
10.17 +†
Employment Agreement, by and between All Market Inc. and Jonathan Burth, dated as of February 10, 2020.
S-1 333 - 259825
10.10 9/27/21
10.18+†
Employment Agreement, by and between All Market Inc. and Charles Van Es, dated as of February 10, 2020.
S-1 333 - 259825
10.12 9/27/21
10.19 +†
Employment Agreement, by and between All Market Inc. and Jane Prior, dated as of February 10, 2020.
S-1 333 - 259825
10.13 9/27/21
10.20 +†
Employment Agreement, by and between The Vita Coco Company, Inc., and Corey Baker, dated as of March 7, 2023
10-Q
001-40950
10.1
5/5/23
10.21 + X
Manufacturing and Purchasing Agreement, by and among Century Agriculture Corporation and All Market Singapore Pte. Ltd., dated as of September 17, 2012.
S-1 333 - 259825
10.14 9/27/21
10.22 + X
Manufacturing and Purchasing Agreement, by and among Fresh Fruit Ingredients, Inc. and All Market, Inc., dated as of April 8, 2010.
S-1 333 - 259825
10.15 9/27/21
10.23 + X
M anufacturing and Purchasing Agreement, by and among Century Pacific Food, Inc. and All Market Singapore Pte. Ltd., dated March 8, 2024.
10-Q
001-40950
10.2
05/02/2024
10.24 + X
C o-Manufacturing and Purchasing Agreement, by and among Axelum Resources Corp. and All Market Singapore Pte. Ltd., dated as of April 18, 2024.
10-Q
001-40950
10.1
08/01/2024
19.1
The Vita Coco Company, Inc. I nsider Trading Policy
*
21.1 List of Subsidiaries of The Vita Coco Company, Inc.
*
23.1 Consent of Deloitte & Touche LLP Independent Registered Public Accounting Firm.
*
31.1 Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
*
31.2 Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
*
32.1 Section 1350 Certification of Chief Executive Officer.
**
98
Table of Contents
32.2 Section 1350 Certification of Chief Financial Officer.
**
97.1
The Vita Coco Company, Inc. Clawback Policy
*
101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document. *
101.SCH Inline XBRL Taxonomy Extension Schema Document. *
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. *
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. *
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. *
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101). *
* Filed herewith.
** Furnished herewith.
† Indicates management contract or compensatory plan.
+ Certain portions of this exhibit (indicated by “####”) have been redacted pursuant to Regulation S-K, Item 601(a)(6).
X Certain portions of this exhibit (indicated by “[***]”) have been redacted pursuant to Regulation S-K, Item 601(b)(10)(iv).
Item 16. Form 10-K Summary.
None.
99
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized .
THE VITA COCO COMPANY, INC.
Date: February 26, 2025
By: /s/ Martin Roper
Martin Roper
Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
Name Title Date
/s/ Martin Roper Chief Executive Officer and Director February 26, 2025
Martin Roper (Principal Executive Officer)
/s/ Corey Baker
Chief Financial Officer
February 26, 2025
Corey Baker
( Principal Financial and Accounting Officer )
/s/ Michael Kirban Chairman and Director February 26, 2025
Michael Kirban
/s/ Aishetu Fatima Dozie Director February 26, 2025
Aishetu Fatima Dozie
/s/ John Leahy
Director February 26, 2025
John Leahy
/s/ Ira Liran
Director February 26, 2025
Ira Liran
/s/ Eric Melloul
Director February 26, 2025
Eric Melloul
/s/ Jane Morreau
Director February 26, 2025
Jane Morreau
/s/ Kenneth Sadowsky
Director February 26, 2025
Kenneth Sadowsky
/s/ John Zupo
Director February 26, 2025
John Zupo
100